The PPARγ pathway determines electrophysiological remodelling and arrhythmia risks in DSC2 arrhythmogenic cardiomyopathy

• Jean‐Baptiste Reisqs,
• Adrien Moreau,
• Azzouz Charrabi,
• Yvonne Sleiman,
• Albano C. Meli,
• Gilles Millat,
• Veronique Briand,
• Philippe Beauverger,
• Sylvain Richard,
• Philippe Chevalier

Affiliations

Jean‐Baptiste Reisqs

Neuromyogene Institute Claude Bernard University, Lyon 1, Villeurbanne France

Adrien Moreau

Université de Montpellier, INSERM, CNRS, PhyMedExp, Montpellier France

Azzouz Charrabi

Université de Montpellier, INSERM, CNRS, PhyMedExp, Montpellier France

Yvonne Sleiman

Université de Montpellier, INSERM, CNRS, PhyMedExp, Montpellier France

Albano C. Meli

Université de Montpellier, INSERM, CNRS, PhyMedExp, Montpellier France

Gilles Millat

Neuromyogene Institute Claude Bernard University, Lyon 1, Villeurbanne France

Veronique Briand

Cardiovascular and Metabolism Research Sanofi R&D, Chilly Mazarin France

Philippe Beauverger

Cardiovascular and Metabolism Research Sanofi R&D, Chilly Mazarin France

Sylvain Richard

Université de Montpellier, INSERM, CNRS, PhyMedExp, Montpellier France

Philippe Chevalier

Neuromyogene Institute Claude Bernard University, Lyon 1, Villeurbanne France